Welcome to our dedicated page for JELD-WEN Holding news (Ticker: $JELD), a resource for investors and traders seeking the latest updates and insights on JELD-WEN Holding stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect JELD-WEN Holding's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of JELD-WEN Holding's position in the market.
JELD-WEN Holding, Inc. reported first-quarter 2024 results with net revenues declining by 11.2% to $959.1 million, driven by lower volume/mix due to weak macro-economic conditions. The company posted a net loss of $(27.7) million, or $(0.32) per share, compared to a profit during the same period last year. Adjusted EBITDA decreased to $68.7 million. The company updated its full-year 2024 guidance, lowering revenue expectations to $3.9-$4.1 billion with a 5-9% decline in Core Revenues compared to 2023. Adjusted EBITDA is expected to be $340-$380 million due to a softened macro-environment.